Please assess the completion status of the following clinical trial:

Trial Title: Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to provide informed consent and able to comply with protocol requirements~* 18 years or older~* Has a COVID-19 diagnosis confirmed by PCR~* Hospitalized within 5 days and meets the following criteria at screening:~Peripheral capillary oxygen saturation (SpO2) ≤ 93% on room air or SpO2 ≥93% on ≤10 liters per minute of supplemental oxygen via nasal cannula~* Radiographic (chest X-ray, computed tomography scan, or ultrasound) evidence of bilateral pulmonary infiltrates consistent with SARS-CoV-2/COVID-19~* Clinical symptoms consistent with COVID-19 per Investigator judgement~* Body mass index between 18 to 40 kg/m2~* If of reproductive potential, willing to abstain or agree to the use of highly effective contraception~Exclusion Criteria:~* Respiratory failure at screening~* History of heart failure~* History of COPD or bronchial asthma~* Active TB or history of TB of the following types~* Uncontrolled arrhythmia within 3 months prior to randomization~* Heart disease of the following types~* Moderate to severe renal insufficiency~* Abnormal white cell and platelet counts~* History of transplantation of vital organs (e.g., heart, lung, liver, and/or kidney);~* Malignant tumor~* Uncontrolled systemic or local autoimmune or inflammatory disease besides SARS-CoV-2~* Unhealed wounds, active gastric ulcer, had surgery~* Received other investigational therapeutic products~* Used interferon therapies~* History of HIV infection, hepatitis B, and/or hepatitis C~* Known serious allergic reaction or hypersensitivity to components of F-652~* Pregnant or breastfeeding~* History of drug abuse or use of narcotics~* Treated with immunomodulators or immunosuppressants~* Other conditions resulting in increased risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- F-652 (Type: EXPERIMENTAL): Patient receives standard care plus F-652
- Placebo (Type: PLACEBO_COMPARATOR): Patient receives standard care plus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).